Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M S Lima

Showing results (131-140 of 171) with videos related to

Pageof 18
Sort By:
Plos One|January 24, 2025
Impacts of continuing education on Primary Health Care professionals-A scoping review protocolLaianny Krizia Maia Pereira, José Adailton da Silva, Ricardo A de M Valentim, et al.
Neurochemical Research|June 29, 2010
Intranigral LPS administration produces dopamine, glutathione but not behavioral impairment in comparison to MPTP and 6-OHDA neurotoxin models of Parkinson's diseaseDeborah Ariza, Marcelo M S Lima, Camila G Moreira, et al.
Protein and Peptide Letters|December 8, 2021
Structural Analysis Revealed the Interaction of Cardenolides from Calotropis procera with Na<sup>+</sup>/K<sup>+</sup> ATPases from HerbivoresMárcio V Ramos, Larissa B N Freitas, Emanuel A Bezerra, et al.
Molecular Neurobiology|June 6, 2018
Dopaminergic Lesion in the Olfactory Bulb Restores Olfaction and Induces Depressive-Like Behaviors in a 6-OHDA Model of Parkinson's DiseaseJessica L Ilkiw, Luana C Kmita, Adriano D S Targa, et al.
Brain Research|October 11, 2014
Neuroprotective and antidepressant-like effects of melatonin in a rotenone-induced Parkinson's disease model in ratsTaysa B Bassani, Raisa W Gradowski, Tiago Zaminelli, et al.
CNS & Neurological Disorders Drug Targets|September 25, 2013
Does Parkinson's disease and type-2 diabetes mellitus present common pathophysiological mechanisms and treatments?Marcelo M S Lima, Adriano D S Targa, Ana C D Noseda, et al.
Jornal De Pediatria|December 31, 2016
Association between postpartum depression and the practice of exclusive breastfeeding in the first three months of lifeCatarine S Silva, Marilia C Lima, Leopoldina A S Sequeira-de-Andrade, et al.
Behavioural Pharmacology|November 9, 2019
Potential new therapies against a toxic relationship: neuroinflammation and Parkinson's diseaseLais S Rodrigues, Juliane Fagotti, Adriano D S Targa, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|March 6, 2014
PPAR-α agonist fenofibrate protects against the damaging effects of MPTP in a rat model of Parkinson's diseaseJanaína K Barbiero, Ronise Santiago, Fernanda S Tonin, et al.
Behavioural Brain Research|August 17, 2014
Neuroprotective effects of peroxisome proliferator-activated receptor alpha and gamma agonists in model of parkinsonism induced by intranigral 1-methyl-4-phenyl-1,2,3,6-tetrahyropyridineJanaína K Barbiero, Ronise M Santiago, Daniele Suzete Persike, et al.
Pageof 18

Showing results (131-140 of 171) with videos related to

Sort By:
Pageof 18
Plos One|January 24, 2025
Impacts of continuing education on Primary Health Care professionals-A scoping review protocolLaianny Krizia Maia Pereira, José Adailton da Silva, Ricardo A de M Valentim, et al.
Neurochemical Research|June 29, 2010
Intranigral LPS administration produces dopamine, glutathione but not behavioral impairment in comparison to MPTP and 6-OHDA neurotoxin models of Parkinson's diseaseDeborah Ariza, Marcelo M S Lima, Camila G Moreira, et al.
Protein and Peptide Letters|December 8, 2021
Structural Analysis Revealed the Interaction of Cardenolides from Calotropis procera with Na<sup>+</sup>/K<sup>+</sup> ATPases from HerbivoresMárcio V Ramos, Larissa B N Freitas, Emanuel A Bezerra, et al.
Molecular Neurobiology|June 6, 2018
Dopaminergic Lesion in the Olfactory Bulb Restores Olfaction and Induces Depressive-Like Behaviors in a 6-OHDA Model of Parkinson's DiseaseJessica L Ilkiw, Luana C Kmita, Adriano D S Targa, et al.
Brain Research|October 11, 2014
Neuroprotective and antidepressant-like effects of melatonin in a rotenone-induced Parkinson's disease model in ratsTaysa B Bassani, Raisa W Gradowski, Tiago Zaminelli, et al.
CNS & Neurological Disorders Drug Targets|September 25, 2013
Does Parkinson's disease and type-2 diabetes mellitus present common pathophysiological mechanisms and treatments?Marcelo M S Lima, Adriano D S Targa, Ana C D Noseda, et al.
Jornal De Pediatria|December 31, 2016
Association between postpartum depression and the practice of exclusive breastfeeding in the first three months of lifeCatarine S Silva, Marilia C Lima, Leopoldina A S Sequeira-de-Andrade, et al.
Behavioural Pharmacology|November 9, 2019
Potential new therapies against a toxic relationship: neuroinflammation and Parkinson's diseaseLais S Rodrigues, Juliane Fagotti, Adriano D S Targa, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|March 6, 2014
PPAR-α agonist fenofibrate protects against the damaging effects of MPTP in a rat model of Parkinson's diseaseJanaína K Barbiero, Ronise Santiago, Fernanda S Tonin, et al.
Behavioural Brain Research|August 17, 2014
Neuroprotective effects of peroxisome proliferator-activated receptor alpha and gamma agonists in model of parkinsonism induced by intranigral 1-methyl-4-phenyl-1,2,3,6-tetrahyropyridineJanaína K Barbiero, Ronise M Santiago, Daniele Suzete Persike, et al.
Pageof 18